COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
30/10/2026
First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care First new FDA-approved treatment [...]
Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD
30/10/2026
The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991). 1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD. 1 The Phase III trial will [...]
Halloween Peptide Sale 2026: Kylo Peptides Announces $1 Research Vial Sale With Orders of $200 or More
30/10/2026
SHERIDAN, Wyo., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ], a U.S. research peptides supplier, today announced a limited-time Halloween sale. Customers who place an order of $200 or [...]
Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation
30/10/2026
Speaking at the Asia-Pacific Conference of German Business in Seoul, Boehringer Ingelheim Chairman of the Board of Managing Directors, Shashank Deshpande, highlights the region’s growing role Boehringer builds on its [...]
Kestra Medical Technologies to Participate in Upcoming Investor Conferences
30/10/2026
KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following [...]
BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
30/10/2026
LOUISVILLE, Ky., Oct. 30, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home- and community-based health services for complex [...]
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
30/10/2026
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders [...]
Regeneron Reports Third Quarter 2026 Financial and Operating Results
30/10/2026
Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 35% to $6.5 billion EYLEA HD ® U.S. net sales increased 62% to $699 million [...]
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
30/10/2026
FDA recently requested additional information to evaluate whether a REMS is necessary for mitapivat in sickle cell disease FDA classified Agios’ response to the information request as a major amendment to the mitapivat [...]
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
30/10/2026
Patent milestones build on positive REMAIN-1 six-month pivotal results and patient research supporting interest in a one-time procedure for post-GLP-1 weight maintenance New catheter patent provides protection extending [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
30/10/2026
Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA [...]
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
30/10/2026
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months [...]
Syndax Announces Participation in November Investor Conferences
30/10/2026
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
30/10/2026
Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending [...]
Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026
30/10/2026
SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
30/10/2026
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company’s precision oncology predictive device for use in the [...]
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
30/10/2026
Completed enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3 [...]
Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)
30/10/2026
90 mg dose of fexlamose administered daily via nebulizer did not demonstrate improvement on trough FEV1, FVC and other spirometric measures with 28 days of dosing in moderate to severe COPD patients. Fexlamose did not [...]

Pages